NO20074594L - 39-Desmetoksy-derivater av rapamycin - Google Patents

39-Desmetoksy-derivater av rapamycin

Info

Publication number
NO20074594L
NO20074594L NO20074594A NO20074594A NO20074594L NO 20074594 L NO20074594 L NO 20074594L NO 20074594 A NO20074594 A NO 20074594A NO 20074594 A NO20074594 A NO 20074594A NO 20074594 L NO20074594 L NO 20074594L
Authority
NO
Norway
Prior art keywords
diseases
rapamycin
treatment
desmethoxy
derivatives
Prior art date
Application number
NO20074594A
Other languages
English (en)
Norwegian (no)
Inventor
Christoph Hendrik Beckmann
Steven James Moss
Rose Mary Sheridan
Mingqiang Zhang
Barrie Wilkinson
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of NO20074594L publication Critical patent/NO20074594L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20074594A 2005-03-11 2007-09-11 39-Desmetoksy-derivater av rapamycin NO20074594L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504994.5A GB0504994D0 (en) 2005-03-11 2005-03-11 Novel compounds
PCT/GB2006/000853 WO2006095185A1 (en) 2005-03-11 2006-03-10 39-desmethoxy derivatives of rapamycin

Publications (1)

Publication Number Publication Date
NO20074594L true NO20074594L (no) 2007-10-15

Family

ID=34508873

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074594A NO20074594L (no) 2005-03-11 2007-09-11 39-Desmetoksy-derivater av rapamycin

Country Status (24)

Country Link
US (2) US7648996B2 (zh)
EP (1) EP1856129B8 (zh)
JP (1) JP5422788B2 (zh)
KR (1) KR20070113282A (zh)
CN (2) CN101175760B (zh)
AU (1) AU2006221786B2 (zh)
BR (1) BRPI0607441A2 (zh)
CA (1) CA2600640C (zh)
CR (1) CR9434A (zh)
DK (1) DK1856129T3 (zh)
ES (1) ES2527530T3 (zh)
GB (1) GB0504994D0 (zh)
HR (1) HRP20150012T1 (zh)
IL (1) IL185688A0 (zh)
MX (1) MX2007011131A (zh)
NI (1) NI200700230A (zh)
NO (1) NO20074594L (zh)
NZ (1) NZ561607A (zh)
PL (1) PL1856129T3 (zh)
PT (1) PT1856129E (zh)
RS (1) RS53778B1 (zh)
RU (1) RU2391346C2 (zh)
WO (1) WO2006095185A1 (zh)
ZA (1) ZA200708601B (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862538B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
JP2008534442A (ja) * 2005-03-11 2008-08-28 バイオティカ テクノロジー リミテッド 化合物の用途
EP1896018A2 (en) * 2005-03-11 2008-03-12 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP1942937A1 (en) * 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
GB0609963D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
EP2132212A1 (en) * 2007-04-05 2009-12-16 Wyeth a Corporation of the State of Delaware Wortmannin-rapamycin conjugate and uses thereof
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PL2310011T3 (pl) 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN104042612A (zh) 2008-11-11 2014-09-17 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
WO2011051960A2 (en) * 2009-09-25 2011-05-05 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2589383A1 (en) * 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
EP3131546B1 (en) 2014-04-16 2022-02-16 Rapamycin Holdings, Inc. Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
CN107073066B (zh) 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1抑制剂
CN106153755B (zh) * 2015-04-24 2020-02-14 山东新时代药业有限公司 2-(叔丁基二甲基硅烷基氧基)乙醇的分析检测方法
EP3341381A4 (en) * 2015-08-28 2019-06-12 Buck Institute for Research on Aging RAPAMYCIN ANALOGUE WITH IMPROVED MTORC1 SPECIFICITY
SG11201908226XA (en) * 2017-02-10 2019-10-30 Mount Tam Therapeutics Inc Rapamycin analog
US20210154372A1 (en) 2017-05-15 2021-05-27 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
UY37900A (es) * 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
CA2102116A1 (en) 1991-05-31 1992-12-01 Gary R. Schulte Use of rapamycin prodrugs as immunosuppressant agents
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
JP3140228B2 (ja) 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5995457A (en) * 1993-12-22 1999-11-30 Jamail; Randall H. Method of masking data on digital video disks (DVD)
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
PT1208847E (pt) 1996-07-30 2007-07-24 Novartis Ag Composições farmacêuticas para o tratamento da rejeição de transplantes, doenças autoimunes ou inflamatórias compreendendo ciclosporina a e 40-0-(2-hidroxietil)-rapamicina
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
AU777997B2 (en) 1999-07-09 2004-11-11 Oregon Health And Science University Compositions and methods for promoting nerve regeneration
CA2407675C (en) 2000-04-27 2012-07-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
PT2762140T (pt) * 2001-02-19 2017-07-04 Novartis Ag Resumo
IL162734A0 (en) * 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
EP1655372A3 (en) * 2002-07-16 2008-01-16 Biotica Technology Limited Production of polyketides and other natural products
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
EP1896018A2 (en) 2005-03-11 2008-03-12 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound

Also Published As

Publication number Publication date
CN101175760B (zh) 2014-08-13
PT1856129E (pt) 2015-01-16
EP1856129A1 (en) 2007-11-21
JP2008532991A (ja) 2008-08-21
IL185688A0 (en) 2008-01-06
ZA200708601B (en) 2009-02-25
JP5422788B2 (ja) 2014-02-19
WO2006095185A1 (en) 2006-09-14
US7648996B2 (en) 2010-01-19
CR9434A (es) 2008-02-22
GB0504994D0 (en) 2005-04-20
CN104211715A (zh) 2014-12-17
RS53778B1 (en) 2015-06-30
US20100081682A1 (en) 2010-04-01
HRP20150012T1 (en) 2015-03-27
EP1856129B1 (en) 2014-10-15
EP1856129B8 (en) 2015-06-03
CN101175760A (zh) 2008-05-07
AU2006221786A1 (en) 2006-09-14
DK1856129T3 (en) 2015-01-05
RU2391346C2 (ru) 2010-06-10
RU2007137668A (ru) 2009-04-20
NZ561607A (en) 2011-01-28
NI200700230A (es) 2008-05-13
MX2007011131A (es) 2007-11-13
US8008318B2 (en) 2011-08-30
CA2600640A1 (en) 2006-09-14
KR20070113282A (ko) 2007-11-28
PL1856129T3 (pl) 2015-08-31
AU2006221786B2 (en) 2012-02-16
CA2600640C (en) 2015-10-27
BRPI0607441A2 (pt) 2010-04-06
US20080188511A1 (en) 2008-08-07
ES2527530T3 (es) 2015-01-26

Similar Documents

Publication Publication Date Title
NO20074594L (no) 39-Desmetoksy-derivater av rapamycin
IL278951A (en) History of 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-6,2-dione and their use in the treatment of IKZF2-dependent diseases
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
EP3668497A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER, INFLAMMATION, OR IMMUNE-REACTION-ASSOCIATED DISEASES
ATE448232T1 (de) Substituierte heterozyklen
CY1122368T1 (el) Παραγωγα 3-οξο-2,3,5,8-τετραϋδρο-[1,2,4]τριαζολο[4,3-α]πυριμιδινης για την αγωγη αναπνευστικων νοσων
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
IL180979A (en) Isoindulin compounds and their use
ECSP104578A (es) Derivados de indolilmaleimida como inhibidores de proteína de cinasa c
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
FR2933979B1 (fr) Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
IL307201A (en) Triazine derivatives and their use in cancer treatment.
EP4186519A4 (en) INTERFERON-BASED CANCER TREATING METHOD AND PHARMACEUTICAL COMPOSITION
EP3915985A4 (en) PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE
EP3814326A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
EP3790866A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
WO2008039409A8 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
EP4361637A3 (en) Method of determining toxicity of an immunomodulatory drug for use in humans
EP4003355A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
EP4219458A3 (en) Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
WO2021097434A8 (en) Fibroblast therapy for inflammatory bowel disease
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
EP4003997A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application